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Figure S 1. Correlation of the specific binding of [18F]AV-1451 in tauopathies (closed black 
dots) and control cases (open grey circles) with tau load as determined by AT8 staining in 
adjacent sections. R2 values without (black) and with (grey) control cases included. 
Abbreviations: AD, Alzheimer’s disease; FTDP-17, frontotemporal dementia with 
parkinsonism linked to chromosome 17 (caused by a mutation of the microtubule-associated 
protein tau (MAPT) gene); PICK, Pick’s disease; CBD, corticobasal degeneration; PSP, 
progressive supranuclear palsy. 
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CBD: R2 = 0.01 (R2 = 0.07) 
















































PICK: R2 = 0.06 (R2 = 0.42) 
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